EPO and Hypertension: Our preclinical data confirm that, by pharmacological inhibition of HIF-PH, the failing kidney can be stimulated to produce sufficient EPO to correct for renal anemia, and that in contrast to treatment with rhEPO, adverse hypertensive effects are not only avoided, but CKD-associated hypertension may be ameliorated by this new therapeutic approach.